{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T03:51:04Z","timestamp":1792813864454,"version":"4.5.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2017,11,10]],"date-time":"2017-11-10T00:00:00Z","timestamp":1510272000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100005972","name":"Deutsche Krebshilfe","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005972","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1007\/s00259-017-3870-6","type":"journal-article","created":{"date-parts":[[2017,11,9]],"date-time":"2017-11-09T21:10:32Z","timestamp":1510261832000},"page":"376-383","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":188,"title":["Absolute number of new lesions on 18F-FDG PET\/CT is more predictive of clinical response than SUV changes in metastatic melanoma patients receiving ipilimumab"],"prefix":"10.1007","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4071-5217","authenticated-orcid":false,"given":"Hoda","family":"Anwar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christos","family":"Sachpekidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Winkler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette","family":"Kopp-Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uwe","family":"Haberkorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica C.","family":"Hassel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonia","family":"Dimitrakopoulou-Strauss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,11,10]]},"reference":[{"key":"3870_CR1","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6","volume":"47","author":"AB Miller","year":"1981","unstructured":"Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer. 1981;47:207\u201314.","journal-title":"Cancer"},{"key":"3870_CR2","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1016\/S0959-8049(99)00229-4","volume":"35","author":"H Young","year":"1999","unstructured":"Young H, Baum R, Cremerius U, Herholz K, Hoekstra O, Lammertsma AA, et al. Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer. 1999;35:1773\u201382.","journal-title":"Eur J Cancer"},{"key":"3870_CR3","doi-asserted-by":"crossref","DOI":"10.1002\/9780470697047","volume-title":"Anticancer therapeutics","author":"S Missailidis","year":"2008","unstructured":"Missailidis S. Anticancer therapeutics. Chichester: Wiley-Blackwell; 2008."},{"key":"3870_CR4","doi-asserted-by":"crossref","first-page":"3005","DOI":"10.1073\/pnas.0712237105","volume":"105","author":"FS Hodi","year":"2008","unstructured":"Hodi FS, Butler M, Oble DA, Seiden MV, Haluska FG, Kruse A, et al. Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc Natl Acad Sci U S A. 2008;105:3005\u201310.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3870_CR5","doi-asserted-by":"crossref","first-page":"7412","DOI":"10.1158\/1078-0432.CCR-09-1624","volume":"15","author":"JD Wolchok","year":"2009","unstructured":"Wolchok JD, Hoos A, O\u2019Day S, Weber JS, Hamid O, Lebb\u00e9 C, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009;15:7412\u201320.","journal-title":"Clin Cancer Res"},{"key":"3870_CR6","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1007\/s00259-014-2944-y","volume":"42","author":"C Sachpekidis","year":"2015","unstructured":"Sachpekidis C, Larribere L, Pan L, Haberkorn U, Dimitrakopoulou-Strauss A, Hassel JC. Predictive value of early 18F-FDG PET\/CT studies for treatment response evaluation to ipilimumab in metastatic melanoma: preliminary results of an ongoing study. Eur J Nucl Med Mol Imaging. 2015;42:386\u201396.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"3870_CR7","doi-asserted-by":"crossref","first-page":"6199","DOI":"10.1200\/JCO.2009.23.4799","volume":"27","author":"CM Balch","year":"2009","unstructured":"Balch CM, Gershenwald JE, Soong S-J, Thompson JF, Atkins MB, Byrd DR, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009;27:6199\u2013206.","journal-title":"J Clin Oncol"},{"key":"3870_CR8","volume-title":"PET and PET\/CT: a clinical guide","author":"E Lin","year":"2009","unstructured":"Lin E, Alavi A. PET and PET\/CT: a clinical guide. New York: Thieme; 2009."},{"key":"3870_CR9","unstructured":"PMOD Technologies. Iso-contour mode (Pseudo-Snake). Z\u00fcrich: PMOD Technologies LLC. \nhttp:\/\/www.pmod.com\/files\/download\/v31\/doc\/pbas\/4729.htm\n\n. Accessed 5 November 2017."},{"key":"3870_CR10","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1016\/S1470-2045(17)30074-8","volume":"18","author":"L Seymour","year":"2017","unstructured":"Seymour L, Bogaerts J, Perrone A, Ford R, Schwartz LH, Mandrekar S, et al. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol. 2017;18:e143\u201352.","journal-title":"Lancet Oncol"},{"key":"3870_CR11","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/328267a0","volume":"328","author":"JF Brunet","year":"1987","unstructured":"Brunet JF, Denizot F, Luciani MF, Roux-Dosseto M, Suzan M, Mattei MG, et al. A new member of the immunoglobulin superfamily \u2013 CTLA-4. Nature. 1987;328:267\u201370.","journal-title":"Nature"},{"key":"3870_CR12","unstructured":"Food and Drug Administration. Yervoy\u00ae (ipilimumab) injection, for intravenous use. Silver Spring, MD: Food and Drug Administration; 2015. \nhttps:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/125377s073lbl.pdf\n\n. Accessed 5 November 2017."},{"key":"3870_CR13","doi-asserted-by":"crossref","DOI":"10.3390\/jcm5100084","volume":"5","author":"EF Goode","year":"2016","unstructured":"Goode EF, Smyth EC. Immunotherapy for gastroesophageal cancer. J Clin Med. 2016;5, 84.","journal-title":"J Clin Med"},{"key":"3870_CR14","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.2217\/fon.15.28","volume":"11","author":"A Dimitrakopoulou-Strauss","year":"2015","unstructured":"Dimitrakopoulou-Strauss A. PET-based molecular imaging in personalized oncology: potential of the assessment of therapeutic outcome. Future Oncol. 2015;11:1083\u201391.","journal-title":"Future Oncol"},{"key":"3870_CR15","first-page":"11N","volume":"54","author":"RL Wahl","year":"2013","unstructured":"Wahl RL. 2013 SNMMI highlights lecture: oncology. J Nucl Med. 2013;54:11N\u201322N.","journal-title":"J Nucl Med"},{"key":"3870_CR16","doi-asserted-by":"crossref","first-page":"340","DOI":"10.2967\/jnumed.109.070946","volume":"51","author":"A Ribas","year":"2010","unstructured":"Ribas A, Benz MR, Allen-Auerbach MS, Radu C, Chmielowski B, Seja E, et al. Imaging of CTLA4 blockade-induced cell replication with (18)F-FLT PET in patients with advanced melanoma treated with tremelimumab. J Nucl Med. 2010;51:340\u20136.","journal-title":"J Nucl Med"},{"key":"3870_CR17","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13550-016-0216-5","volume":"6","author":"C-M Breki","year":"2016","unstructured":"Breki C-M, Dimitrakopoulou-Strauss A, Hassel J, Theoharis T, Sachpekidis C, Pan L, et al. Fractal and multifractal analysis of PET\/CT images of metastatic melanoma before and after treatment with ipilimumab. EJNMMI Res. 2016;6:61.","journal-title":"EJNMMI Res"},{"key":"3870_CR18","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1111\/pcmr.12503","volume":"29","author":"BY Kong","year":"2016","unstructured":"Kong BY, Menzies AM, Saunders CAB, Liniker E, Ramanujam S, Guminski A, et al. Residual FDG-PET metabolic activity in metastatic melanoma patients with prolonged response to anti-PD-1 therapy. Pigment Cell Melanoma Res. 2016;29:572\u20137.","journal-title":"Pigment Cell Melanoma Res"},{"key":"3870_CR19","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.2967\/jnumed.116.188839","volume":"58","author":"SY Cho","year":"2017","unstructured":"Cho SY, Lipson EJ, Im H-J, Rowe SP, Gonzalez EM, Blackford A, et al. Prediction of response to immune checkpoint inhibitor therapy using early-time-point 18F-FDG PET\/CT imaging in patients with advanced melanoma. J Nucl Med. 2017;58:1421\u20138.","journal-title":"J Nucl Med"},{"issue":"Suppl 1","key":"3870_CR20","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s00259-017-3691-7","volume":"44","author":"AN Wong","year":"2017","unstructured":"Wong AN, McArthur GA, Hofman MS, Hicks RJ. The advantages and challenges of using FDG PET\/CT for response assessment in melanoma in the era of targeted agents and immunotherapy. Eur J Nucl Med Mol Imaging. 2017;44(Suppl 1):67\u201377.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"3870_CR21","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1158\/2326-6066.CIR-15-0102","volume":"3","author":"SH Tirumani","year":"2015","unstructured":"Tirumani SH, Ramaiya NH, Keraliya A, Bailey ND, Ott PA, Hodi FS, et al. Radiographic profiling of immune-related adverse events in advanced melanoma patients treated with Ipilimumab. Cancer Immunol Res. 2015;3:1185\u201392.","journal-title":"Cancer Immunol Res"},{"key":"3870_CR22","first-page":"662","volume":"14","author":"KC K\u00e4hler","year":"2016","unstructured":"K\u00e4hler KC, Hassel JC, Heinzerling L, Loquai C, M\u00f6ssner R, Ugurel S, et al. Management of side effects of immune checkpoint blockade by anti-CTLA-4 and anti-PD-1 antibodies in metastatic melanoma. J Dtsch Dermatol Ges. 2016;14:662\u201381.","journal-title":"J Dtsch Dermatol Ges"},{"key":"3870_CR23","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.acra.2016.08.005","volume":"24","author":"JW Wachsmann","year":"2017","unstructured":"Wachsmann JW, Ganti R, Peng F. Immune-mediated disease in Ipilimumab immunotherapy of melanoma with FDG PET-CT. Acad Radiol. 2017;24:111\u20135.","journal-title":"Acad Radiol"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00259-017-3870-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-017-3870-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-017-3870-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,1,26]],"date-time":"2018-01-26T23:59:14Z","timestamp":1517011154000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00259-017-3870-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,10]]},"references-count":23,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["3870"],"URL":"https:\/\/doi.org\/10.1007\/s00259-017-3870-6","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,10]]}}}